): Myeloperoxidase (MPO) has been identified as a risk factor for Alzheimer's disease based on the detection of this myeloid-specific enzyme in amyloid plaques, along with Abeta42, and the association of a n463 G/A promoter polymorphism with increased incidence and earlier onset of disease. MPO catalyzes a reaction between H2O2 and chloride to generate hypochlorous acid (HOCl), a potent oxidant with cytotoxic effects. In normal brain tissue, MPO is not present in the abundant brain microglia, but is present in reactive microglia surrounding plaques in Alzheimer's disease brain, suggesting that MPO gene expression is induced by Abeta or other plaque components. The highest levels of MPO deposition in plaques are detected in ApoE4 carriers, suggesting a link between MPO A allele and ApoE4, the major risk factor for sporadic Alzheimer's disease. Recent genetic evidence further indicates that the MPO A allele and ApoE4 synerigize to increase AD risk for males, while the MPO G allele has been linked to increased risk for females. The n463 G/A polymorphism creates an estrogen receptor-binding site in the MPO A promoter which may form the basis for this gender difference in genotype association with Alzheimer's disease. The experiments in this proposal will further define the role of MPO in Alzheimer's disease, elucidate the mechanism by which MPO and ApoE4 synergize to increase the risk of Alzheimer's disease, and determine the reason for the gender difference in MPO genotype association with AD risk. The experimental design will include analysis of human AD brain tissue, and make extensive use of mouse models expressing genetic risk factors for human Alzheimer's disease.
The Specific Aims are: (1) to investigate the mechanism by which MPO contributes to Alzheimer's disease; (2) to investigate the basis for the gender difference in MPO genotype association with Alzheimer's disease; (3) to investigate the mechanism by which ApoE4 and MPO synergize to increase AD risk; and (4) to investigate how the normally quiescent MPO gene is induced in brain microglia in Alzheimer's disease. MPO is a reasonable target for therapeutics aimed at slowing the progression of Alzheimer's disease. An inhibitor of MPO has been previously noted to reduce AD incidence in a large study.
|Laura, Richard P; Dong, David; Reynolds, Wanda F et al. (2016) T47D Cells Expressing Myeloperoxidase Are Able to Process, Traffic and Store the Mature Protein in Lysosomes: Studies in T47D Cells Reveal a Role for Cys319 in MPO Biosynthesis that Precedes Its Known Role in Inter-Molecular Disulfide Bond Formation. PLoS One 11:e0149391|
|Maki, Richard A; Tyurin, Vladimir A; Lyon, Robert C et al. (2009) Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. J Biol Chem 284:3158-69|
|Reynolds, Wanda F; Sermet-Gaudelus, Isabelle; Gausson, Valerie et al. (2006) Myeloperoxidase promoter polymorphism -463G is associated with more severe clinical expression of cystic fibrosis pulmonary disease. Mediators Inflamm 2006:36735|
|Castellani, Lawrence W; Chang, James J; Wang, Xuping et al. (2006) Transgenic mice express human MPO -463G/A alleles at atherosclerotic lesions, developing hyperlipidemia and obesity in -463G males. J Lipid Res 47:1366-77|
|Reynolds, Wanda F; Kumar, Alan P; Piedrafita, F Javier (2006) The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands. Biochem Biophys Res Commun 349:846-54|
|Kumar, Alan P; Reynolds, Wanda F (2005) Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun 331:442-51|
|Kumar, Alan P; Ryan, Colm; Cordy, Victoria et al. (2005) Inducible nitric oxide synthase expression is inhibited by myeloperoxidase. Nitric Oxide 13:42-53|
|Kumar, Alan P; Piedrafita, F Javier; Reynolds, Wanda F (2004) Peroxisome proliferator-activated receptor gamma ligands regulate myeloperoxidase expression in macrophages by an estrogen-dependent mechanism involving the -463GA promoter polymorphism. J Biol Chem 279:8300-15|
|Reynolds, Wanda F; Stegeman, Coen A; Tervaert, Jan W Cohen (2002) -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis. Clin Immunol 103:154-60|
|Reynolds, W F; Patel, K; Pianko, S et al. (2002) A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection. Genes Immun 3:345-9|